类风湿关节炎的慢病管理
王宏智, 袁昳玮 . 类风湿关节炎的慢病管理[J]. 内科理论与实践, 2022 , 17(03) : 202 -207 . DOI: 10.16138/j.1673-6087.2022.03.006
| [1] | 田新平, 李梦涛, 曾小峰. 我国类风湿关节炎诊治现状与挑战:来自中国类风湿关节炎2019年年度报告[J]. 中华内科杂志, 2021, 60(7): 593-598. |
| [2] | 周云杉, 王秀茹, 安媛, 等. 全国多中心类风湿关节炎患者残疾及功能受限情况的调查[J]. 中华风湿病学杂志, 2013, 17(8): 526-532. |
| [3] | Massarenti L, Enevold C, Damgaard D, et al. PADI4 polymorphisms confer risk of anti-CCP-positive rheumatoid arthritis in synergy with HLA-DRB1*04 and smoking[J]. Front Immunol, 2021, 12: 707690. |
| [4] | Larid G, Pancarte M, Offer G, et al. In rheumatoid arthritis patients, HLA-DRB1*04:01 and rheumatoid nodules are associated with ACPA to a particular fibrin epitope[J]. Front Immunol, 2021, 12: 692041. |
| [5] | Arleevskaya M, Takha E, Petrov S, et al. Causal risk and protective factors in rheumatoid arthritis[J]. J Transl Autoimmun, 2021, 4: 100119. |
| [6] | Hashimoto A, Matsui T. Risk of serious infection in patients with rheumatoid arthritis[J]. Nihon Rinsho Meneki Gakkai Kaishi, 2015, 38(2): 109-115. |
| [7] | Liu Z, Wu Y, Luo Y, et al. Self-balance of intestinal flora in spouses of patients with rheumatoid arthritis[J]. Front Med (Lausanne), 2020, 7: 538. |
| [8] | Drummond PD, Willox M. Painful effects of auditory startle, forehead cooling and psychological stress in patients with fibromyalgia or rheumatoid arthritis[J]. J Psychosom Res, 2013, 74(5): 378-383. |
| [9] | Adawi M, Sabbah F, Tzischinsky O, et al. Sleep disorders and vascular responsiveness in patients with rheumatoid arthritis[J]. J Intern Med, 2020, 288(4): 439-445. |
| [10] | Anderson R, Meyer PW, Ally MM, et al. Smoking and air pollution as pro-inflammatory triggers for the development of rheumatoid arthritis[J]. Nicotine Tob Res, 2016, 18(7): 1556-1565. |
| [11] | Bae SC, Lee YH. Alcohol intake and risk of rheumatoid arthritis: a Mendelian randomization study[J]. Z Rheumatol, 2019, 78(8): 791-796. |
| [12] | Meisters R, Putrik P, Ramiro S, et al. EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries[J]. Ann Rheum Dis, 2020, 79(11): 1423-1431. |
| [13] | 蒋黎纯, 杨清萍, 王宏智. 嘉兴地区人群维生素D水平及其影响因素[J]. 中华骨质疏松和骨矿盐疾病杂志, 2017, 10(4): 375-377. |
| [14] | Fukuda W, Omoto A, Oku S, et al. Contribution of rheumatoid arthritis disease activity and disability to rheumatoid cachexia[J]. Mod Rheumatol, 2010, 20(5): 439-443. |
| [15] | Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[J]. Arthritis Rheum,1988, 31(3): 315-324. |
| [16] | Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Arthritis Rheum, 2010, 62(9): 2569-2581. |
| [17] | Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis[J]. Lancet, 2017, 389(10086): 2338-2348. |
| [18] | van der Linden MP, Knevel R, Huizinga TW, et al. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria[J]. Arthritis Rheum, 2011, 63(1): 37-42. |
| [19] | 叶华, 苏茵, 李茹, 等. 早期类风湿关节炎分类标准的全国多中心临床验证[J]. 中华风湿病学杂志, 2014, 18(12): 802-805. |
| [20] | Thevissen K, Vercoutere W, Bombardier C, et al. Diagnostic and prognostic value of synovial biopsy in adult undifferentiated peripheral inflammatory arthritis[J]. J Rheumatol Suppl, 2011, 87: 45-47. |
| [21] | 中华医学会风湿病学分会. 2018中国类风湿关节炎诊疗指南[J]. 中华内科杂志, 2018, 57(4): 242-251. |
| [22] | Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis[J]. Arthritis Care Res (Hoboken), 2021, 73(7): 924-939. |
| [23] | 风湿免疫疾病慢病管理全国护理协作组. 类风湿关节炎患者的慢病管理专家共识(2014版)[J]. 中华风湿病学杂志, 2016, 20(2): 127-131. |
| [24] | 曾小峰, 魏李培. 风湿免疫科医生奇缺[N]. 健康报,2013-07-01(007). |
| [25] | Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial[J]. Lancet, 2004, 364(9430): 263- |
| [26] | Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study[J]. Ann Rheum Dis, 2011, 70(6): 1039-1046. |
| [27] | Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force[J]. Ann Rheum Dis, 2010, 69(4): 631-637. |
| [28] | Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis[J]. Arthritis Care Res (Hoboken), 2016, 68(1): 1-25. |
| [29] | Yu Z, Lu B, Agosti J, et al. Implementation of treat-to-target for rheumatoid arthritis in the US: analysis of baseline data from a randomized controlled trial[J]. Arthritis Care Res (Hoboken), 2018, 70(5): 801-806. |
| [30] | Lau CS, Chia F, Dans L, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis[J]. Int J Rheum Dis, 2019, 22(3): 357-375. |
| [31] | Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update[J]. Ann Rheum Dis, 2020, 79(6): 685-699. |
| [32] | Allen A, Carville S, McKenna F, et al. Diagnosis and management of rheumatoid arthritis in adults: summary of updated NICE guidance[J]. BMJ, 2018, 362 : k3015. |
| [33] | Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update[J]. Ann Rheum Dis, 2017, 76(6): 960-977. |
| [34] | Nagy G, Roodenrijs NMT, Welsing PMJ, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis[J]. Ann Rheum Dis, 2021, 81(1): 20-33. |
| [35] | Smolen JS, Boers M, Abadie EC, et al. Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA[J]. Curr Med Res Opin, 2011, 27(2): 315-325. |
| [36] | Rannio T, Asikainen J, Kokko A, et al. Early remission is a realistic target in a majority of fatients with DMARD-naive rheumatoid arthritis[J]. J Rheumatol, 2016, 43(4): 699-706. |
| [37] | Mathias K, Amarnani A, Pal N, et al. Chronic pain in patients with rheumatoid arthritis[J]. Curr Pain Headache Rep, 2021, 25(9): 59. |
| [38] | Elangovan S, Tan YK. The role of musculoskeletal ultrasound imaging in rheumatoid arthritis[J]. Ultrasound Med Biol, 2020, 46(8): 1841-1853. |
| [39] | Jaffe DH, Lee L, Huynh S, et al. Health Inequalities in the Use of Telehealth in the United States in the Lens of COVID-19[J]. Popul Health Manag, 2020, 23(5): 368-377. |
| [40] | Chang JE, Lai AY, Gupta A, et al. Rapid transition to telehealth and the digital divide:implications for primary care access and equity in a post-COVID era[J]. Milbank Q, 2021, 99(2): 340-368. |
/
| 〈 |
|
〉 |
